Close Menu

NEW YORK – IncellDx and Factorial Diagnostics have inked an exclusive license and supply agreement for technology to develop their multi-omic cancer diagnostic workflow.

San Carlos, California-based Factorial will use InCellDx's new IncellMax-Seq reagent to perform in situ library preparation for next-generation sequencing (NGS) applications.

The firms believe the collaboration will allow simultaneous immunophenotyping capabilities, along with unequivocal cell pre-identification.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.